Clinical trials
Obesity, Abdominal trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 43 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cairo University | 3 |
| Hubei Hospital of Traditional Chinese Medicine | 2 |
| Laval University | 2 |
| McMaster University | 2 |
| Assiut University | 1 |
| Azienda Ospedaliera Universitaria Integrata Verona | 1 |
| Azienda Ospedaliera, Ospedale Civile di Legnano | 1 |
| Badr University | 1 |
| Baker Heart and Diabetes Institute | 1 |
| Dongfang Hospital Beijing University of Chinese Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity, Abdominal | 43 |
| Obesity | 15 |
| Hypertension | 7 |
| Diabetes Mellitus | 6 |
| Metabolic Syndrome | 6 |
| Insulin Resistance | 5 |
| Overweight | 5 |
| Body Weight | 3 |
| Cardiovascular Diseases | 3 |
| Diabetes Mellitus, Type 2 | 3 |
Trials
Showing 51 to 43 of 43. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.